HomeCompareSTRCW vs JNJ

STRCW vs JNJ: Dividend Comparison 2026

STRCW yields 4000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STRCW wins by $7175340620755.84M in total portfolio value
10 years
STRCW
STRCW
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full STRCW calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — STRCW vs JNJ

📍 STRCW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTRCWJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STRCW + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STRCW pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STRCW
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, STRCW beats the other by $5,813,155,604,218,156,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STRCW + JNJ for your $10,000?

STRCW: 50%JNJ: 50%
100% JNJ50/50100% STRCW
Portfolio after 10yr
$3587670310377.95M
Annual income
$3,419,503,296,598,920,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

STRCW
Analyst Ratings
3
Hold
Consensus: Hold
Altman Z
-7.3
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STRCW buys
0
JNJ buys
0
No recent congressional trades found for STRCW or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTRCWJNJ
Forward yield4000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$7175340620755.87M$30.5K
Annual income after 10y$6,839,006,593,197,835,000.00$4,749.88
Total dividends collected$7152397773804.84M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: STRCW vs JNJ ($10,000, DRIP)

YearSTRCW PortfolioSTRCW Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$410,700$400,000.00$10,594$274.49+$400.1KSTRCW
2$15,792,720$15,353,271.03$11,294$360.69+$15.78MSTRCW
3$568,657,142$551,758,931.89$12,133$476.91+$568.65MSTRCW
4$19,176,207,860$18,567,744,718.20$13,156$635.42+$19176.19MSTRCW
5$605,696,028,890$585,177,486,479.73$14,432$854.61+$605696.01MSTRCW
6$17,922,210,653,594$17,274,115,902,681.27$16,056$1,162.76+$17922210.64MSTRCW
7$496,869,793,504,300$477,693,028,104,954.00$18,175$1,604.53+$496869793.49MSTRCW
8$12,908,672,105,251,704$12,377,021,426,202,104.00$21,009$2,252.68+$12908672105.23MSTRCW
9$314,330,866,876,668,540$300,518,587,724,049,200.00$24,911$3,229.73+$314330866876.64MSTRCW
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$30,458$4,749.88+$7175340620755.84MSTRCW

STRCW vs JNJ: Complete Analysis 2026

STRCWStock

Sarcos Corp., a robotics and sensor company, designs, builds, and produces dexterous tele-operated robotic systems. Its products include Guardian S, an unmanned ground vehicle for security, inspection, and non-destructive testing available in a Robot-as-a-Service offering; Guardian GT, a big arm system or dual-armed human-controlled robot mounted on an agile tracked vehicle base for commercial, industrial, and first responder environments; and Guardian XO, a robot that features an exoskeleton suit; SenSuit controller garment for enhanced teleoperation of the Guardian XT (a highly dexterous mobile robotic system); and humanoid solutions. The company also provides advanced robotic systems for industry, entertainment; medical devices, including artificial limbs and vascular systems; and mechanical and electrical microsystems for practical applications. The company serves healthcare, life sciences, telecommunications, robotics, defense, and entertainment industries. Sarcos Corp. was founded in 1983 and is based in Salt Lake City, Utah with an additional office in Bellevue, Washington. Sarcos Corp. is a former subsidiary of Raytheon Company.

Full STRCW Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this STRCW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STRCW vs SCHDSTRCW vs JEPISTRCW vs OSTRCW vs KOSTRCW vs MAINSTRCW vs ABBVSTRCW vs MRKSTRCW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.